Skip to main content
Charcot (neuropathic) arthropathy of elbow due to Syringomyelia - review of 50 pts. Median age 45 yrs, 2/3 isolated elbo

Dr. John Cush RheumNow

4 years ago
Charcot (neuropathic) arthropathy of elbow due to Syringomyelia - review of 50 pts. Median age 45 yrs, 2/3 isolated elbow arthritis; other joints: shoulder > wrist > MCPs/IPs. 2/3 had Chiari malformations, sensory/motor deficits, or ulnar neuropathy https://t.co/KjOpAKxs6i https://t.co/87Asmlzq3K
Matched cohort study of survival in 1139 incident systemic sclerosis pts & 5613 controls. W/ median F/U of 5-6 yrs,

Dr. John Cush RheumNow

4 years ago
Matched cohort study of survival in 1139 incident systemic sclerosis pts & 5613 controls. W/ median F/U of 5-6 yrs, deaths were 268 vs 554. 5 Yr survival was lower 79.8% vs 92.9% (10yr survival 67.7% vs 84.8%). SSc had higher 1 yrs mortality (HR 3.7) https://t.co/rGlTWUVVMU https://t.co/XeKnjldgye
Review of VTE risk with JAK inhibitors
- Tofacitinib: 10mg or 5 mg bid - PE rates 0.5 & 0.3/100PY; higher w/ risk

Dr. John Cush RheumNow

4 years ago
Review of VTE risk with JAK inhibitors - Tofacitinib: 10mg or 5 mg bid - PE rates 0.5 & 0.3/100PY; higher w/ risk factors, VTE 0.35/100PY - Baricitinib: IR of DVT/PE was 0.5/100PY - Filgotinib: 200mg VTEs 0.2/100PY Most VTE occured in LT extension of RCT https://t.co/xeX4wj4cWU https://t.co/CJV2h9zO9a
Axial Psoriatic Arthritis and Ankylosing Spondylitis with Psoriasis

A cohort analysis from Toronto suggests that axial

Dr. John Cush RheumNow

4 years ago
Axial Psoriatic Arthritis and Ankylosing Spondylitis with Psoriasis A cohort analysis from Toronto suggests that axial psoriatic arthritis (PsA) is distinctly different from axial ankylosing spondylitis (AS) with psoriasis. https://t.co/9rFGMLtV5Z https://t.co/3L4mid8i0n
A recent meta-analysis suggests a bidirectional association between rheumatoid arthritis (RA) and depression.  Finding RA patients with depression yields an 80% increased mortality risk. Anti-cytokine therapies represents a potential alternative for the treatment of depression. Analysis of 11 cohort studies included 39,130 RA patients, 550,782 patients with depression and 7,802,230 controls.
Weight Loss Slows Knee OA Progression
  • MedPage Today
Declines in body mass index (BMI) were linked with slower worsening of knee osteoarthritis (OA), according to data from three large longitudinal cohort studies.
Anti-rheumatics drug market accounted for $57 billion in sales in 2018 and is expected to reach nearly $72 billion by 20

Dr. John Cush RheumNow

4 years ago
Anti-rheumatics drug market accounted for $57 billion in sales in 2018 and is expected to reach nearly $72 billion by 2026, registering a CAGR of 2.9% from 2019 to 2026. https://t.co/X77cx5QM4G https://t.co/eNCvemksWK
Look-alike Humans identified by facial recognition algorithms identify found to share common genetic sequences such as f

Dr. John Cush RheumNow

4 years ago
Look-alike Humans identified by facial recognition algorithms identify found to share common genetic sequences such as face trait variants. DNA methylation & microbiome profiles only contribute modestly to human likeness. https://t.co/2KjFAmhPvi https://t.co/RBjHObv2RU
73 #RA pregnancies w/ live births. 88% were in remission/low disease before conception. RA flares occurred in 37% (in 1s

Dr. John Cush RheumNow

4 years ago
73 #RA pregnancies w/ live births. 88% were in remission/low disease before conception. RA flares occurred in 37% (in 1st &2nd trim). Preterm assoc w/ Flares; flares more likely if bDMARD D/C @ +Preg test (55% w/ flare vs. 30% w/o flare, p 0.03, OR 2.9) https://t.co/hVtUuX3lfr https://t.co/bFbyQZbcim
Chinese study of 215 Bx proven #SLE pts - all rx w/ IV CTX+steroids. Responders were given either AZA or leflunomide. Re

Dr. John Cush RheumNow

4 years ago
Chinese study of 215 Bx proven #SLE pts - all rx w/ IV CTX+steroids. Responders were given either AZA or leflunomide. Renal outcomes were same w/ LEF or AZA as maintenance. Flares (16% vs 18%), Time to flare (16 v 14 mos), AE, proteinuria https://t.co/Ad7Ec4OPco https://t.co/NoKAgiMKrK
Survey of 3357 retired Olympians (45 yrs) shows same OA rates as 1735 gen population (41yrs) - #OA in 23% (knee 7.4%,

Dr. John Cush RheumNow

4 years ago
Survey of 3357 retired Olympians (45 yrs) shows same OA rates as 1735 gen population (41yrs) - #OA in 23% (knee 7.4%, hip, ankle). OA from Injury, age, obesity. Prior knee/hip injury increased OA rates significantly (aOR 1.51/4.03) https://t.co/JwaAidkGG1 https://t.co/30Zm7bDWUG
A cohort analysis from Toronto suggests that axial psoriatic arthritis (PsA) is distinctly different from axial ankylosing spondylitis (AS) with psoriasis. Researchers examined two PsA and AS cohorts -  patients with PsA with axial disease and isolated axial patients with AS with psoriasis. 
Cochrane review of Stem cell transplantation in systemic sclerosis (3RCTs w/ 125 pts). Non‐myeloablative & myeloab

Dr. John Cush RheumNow

4 years ago

Cochrane review of Stem cell transplantation in systemic sclerosis (3RCTs w/ 125 pts). Non‐myeloablative & myeloablative selective HSCT had moderate evidence for improved survival, skin thickness & function. But these had high Serious AE rates. https://t.co/sGzWYLwcAZ https://t.co/7JiR0fe3GY

A current Medscape article on patient "no shows" in private medical practice examines the cause and approach to the problem. The most common reason for no shows is lack of knowledge about the scheduled appointment. Here are other common causes of no-shows, and how to address the problem.
JAK-pot study of 19 registries, 31,846 RA pts Rx w/ new drugs shows equal CDAI efficacy for TNFi (54%), ABA (50%), IL-6i

Dr. John Cush RheumNow

4 years ago
JAK-pot study of 19 registries, 31,846 RA pts Rx w/ new drugs shows equal CDAI efficacy for TNFi (54%), ABA (50%), IL-6i (55%), & JAKi (56%). Most D/C for LOE. Compared to TNFi, JAKi and IL-6i were d/c more for adverse events, less for ineffectiveness https://t.co/FlqPUVdWaC https://t.co/BZnpwtB8SY
×